GALILEO Trial of Rivaroxaban After TAVR Stopped Early for Harm | tctmd.com
ESC 365 - Doctor Georg Marcus Froehlich
Rivaroxaban-based antithrombotic strategy vs antiplatelet-based strategy after TAVR to optimize clinical outcomes: GALILEO
Full GALILEO Results Confirm Harm With Rivaroxaban After TAVR | tctmd.com
On Trial for Reason: Science, Religion, and Culture in the Galileo Affair, by Maurice Finocchiaro | Times Higher Education (THE)
Anticoagulation Therapy in Patients Post-TAVR - ppt download
Trial design: Rivaroxaban for the prevention of major cardiovascular events after transcatheter aortic valve replacement: Rationale and design of the GALILEO study - ScienceDirect
A controlled trial of rivaroxaban after transcatheter aortic-valve replacement (GALILEO)
Antithrombotic Therapy After Transcatheter Aortic Valve Replacement | Circulation: Cardiovascular Interventions
Optimal Antithrombotic Strategy After Transcatheter Aortic Valve Replacement: Is the “Less Is More” Concept Always Better? | Journal of the American Heart Association
GALILEO
Galileo
Galileo Research Fact Sheet #138: Can Galileo Therapy decrease the development of Scoliosis? - Novotec Medical und Stratec Medizintechnik GmbH
Clinical Trial Results in MEfRVO | EYLEA® (aflibercept) Injection
OAC in TAVR: Failed Galileo
On The Behalf of The GALILEO Investigators - ppt download
GALILEO 4D - STUDY DESIGN
The ATLANTIS Randomized Trial: Apixaban Versus Standard of Care After TAVI - Cardiac Interventions Today
A Controlled Trial of Rivaroxaban after Transcatheter Aortic-Valve Replacement | NEJM
A Controlled Trial of Rivaroxaban after Transcatheter Aortic-Valve Replacement | NEJM
Rationale and design of the ADAPT-TAVR trial: a randomised comparison of edoxaban and dual antiplatelet therapy for prevention of leaflet thrombosis and cerebral embolisation after transcatheter aortic valve replacement | BMJ Open
Antithrombotic Therapy After Transcatheter Aortic Valve Replacement | JACC: Cardiovascular Interventions
Predicting the Future: Will the Ongoing GALILEO and ENVISAGE AF Trials Change How We Anticoagulate Patients After TAVR? | tctmd.com
The GALILEO Trial: Inova Researchers Study New Drug Therapy for Heart Patients - Inova Newsroom
PDF) Trial design: Rivaroxaban for the prevention of major cardiovascular events after transcatheter aortic valve replacement: Rationale and design of the GALILEO study
A Controlled Trial of Rivaroxaban after Transcatheter Aortic-Valve Replacement | NEJM
